This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses. All drugs listed are approved specifically for major depressive disorder unless noted otherwise.
Opipramol (Insidon), tianeptine (Stablon, Coaxil) and amineptine (discontinued; formerly Survector, Maneon) are chemically TCAs but are pharmacodynamically atypical, and are therefore grouped elsewhere.
Amitriptyline/chlordiazepoxide (Limbitrol) – TCA and benzodiazepine combination
Amitriptyline/perphenazine (Etafron) – TCA and typical antipsychotic combination
Flupentixol/melitracen (Deanxit) – TCA and typical antipsychotic combination
Olanzapine/fluoxetine (Symbyax) – SSRI and atypical antipsychotic combination – approved as a monotherapy for bipolar depression and treatment-resistant depression
Tranylcypromine/trifluoperazine (Parstelin, Parmodalin, Jatrosom N, Stelapar) – MAOI and typical antipsychotic combination
↑Tatsumi, M; Groshan, K; Blakely, RD; Richelson, E (11 December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters.". European Journal of Pharmacology340 (2–3): 249–58. doi:10.1016/s0014-2999(97)01393-9. PMID9537821.
↑"A systematic review of augmentation strategies for patients with major depressive disorder". Psychopharmacol Bull42 (3): 57–90. 2009. PMID19752841.
↑ 5.05.1"A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". J Clin Psychiatry75 (9): 1010–8. September 2014. doi:10.4088/JCP.13r08851. PMID25295426.
↑"Methylphenidate: established and expanding roles in symptom management". Am J Hosp Palliat Care29 (6): 483–90. 2012. doi:10.1177/1049909111427029. PMID22144657.
↑"Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". Eur Neuropsychopharmacol27 (5): 423–441. May 2017. doi:10.1016/j.euroneuro.2017.03.003. PMID28318897.
↑"Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials". Bipolar Disord22 (2): 109–120. March 2020. doi:10.1111/bdi.12859. PMID31643130.
↑"Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis". Acta Psychiatr Scand135 (6): 527–538. June 2017. doi:10.1111/acps.12712. PMID28256707.
↑"Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?". Psychiatr. Clin. North Am.39 (3): 477–86. 2016. doi:10.1016/j.psc.2016.04.008. PMID27514300.